Angiodynamics Inc (ANGO): Stephen A Trowbridge , SVP and General Counsel of Angiodynamics Inc sold 12,940 shares on Apr 21, 2016. The Insider selling transaction was reported by the company on Apr 25, 2016 to the Securities and Exchange Commission. The shares were sold at $12.26 per share for a total value of $159,184.20 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Feb 19, 2015, Stark Richard (SVP, GM – Oncology) sold 18,100 shares at $18.53 per share price.
AngioDynamics: On Friday, Apr 22, 2016 heightened volatility was witnessed in AngioDynamics which led to swings in the share price. The shares opened for trading at $12.41 and hit $12.62 on the upside , eventually ending the session at $12.44, with a gain of 0.48% or 0.06 points. The heightened volatility saw the trading volume jump to 78,906 shares. The 52-week high of the share price is $17.46 and the company has a market cap of $452 M . The 52-week low of the share price is at $9.71.
Company has been under the radar of several Street Analysts.AngioDynamics is Resumed by Piper Jaffray to Neutral. The Rating was issued on Apr 8, 2016.
AngioDynamics Inc. designs manufactures and sells a range of medical surgical and diagnostic devices used by professional healthcare providers for vascular access for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive image-guided procedures. The Company offers products within three product groupings: Peripheral Vascular Vascular Access and Oncology/Surgery. The Company’s Peripheral Vascular products include fluid management venous thrombus management as well as other core products. The Company’s BioFlo products incorporate Endexo technology into the manufacturing and design of its Vascular Access products. Its Oncology/Surgery product offerings include its microwave ablation products its radiofrequency ablation (RFA) and its NanoKnife product lines.